Vertex Reports First-Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Vertex Reports First-Quarter 2017 Financial Results
April 28, 2017 6:26 AM EDT
Credit Suisse raised its price target on Vertex (NASDAQ: VRTX) to $125.00 (from $108.00) while maintaining a Outperform rating.
Analyst Alethia Young raised their probability of success to 75% from 50% to the triplet in the HetMin population. They model $2.1B in peak sales in HetMin.
...
More
April 27, 2017 4:18 PM EDT
Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $481 million versus the consensus estimate of $510.6 million.
"During the quarter, our progress toward treating more people with CF was marked by several important milestones, including expanding the number of people being treated with our approved medicines and developing potential new medicines to treat all people with CF in the future," said Jeffrey Leiden, M.D., Ph.D., Chairman,... More
